Procoagulant Microvesicles in COVID-19 Patients: Possible Modulators of Inflammation and Prothrombotic Tendency.
COVID-19
D-dimer
NLR
PLR
PNR
microvesicles
procoagulant
tissue factor
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
12
2021
accepted:
20
04
2022
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
7
5
2022
Statut:
epublish
Résumé
The hypercoagulability and thrombotic tendency in coronavirus disease 2019 (COVID-19) is multifactorial, driven mainly by inflammation, and endothelial dysfunction. Elevated levels of procoagulant microvesicles (MVs) and tissue factor-bearing microvesicles (TF-bearing MVs) have been observed in many diseases with thrombotic tendency. The current study aimed to measure the levels of procoagulant MVs and TF-bearing MVs in patients with COVID-19 and healthy controls and to correlate their levels with platelet counts, D-Dimer levels, and other proposed calculated inflammatory markers. Forty ICU-admitted patients with COVID-19 and 37 healthy controls were recruited in the study. Levels of procoagulant MVs and TF-bearing MVs in the plasma of the study population were measured using enzyme linked immunosorbent assay. COVID-19 patients had significantly elevated levels of procoagulant MVs and TF-bearing MVs as compared with healthy controls (P<0.001). Procoagulant MVs significantly correlated with TF-bearing MVs, D-dimer levels, and platelet count, but not with calculated inflammatory markers (neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and platelet/neutrophil ratio). Elevated levels of procoagulant MVs and TF-bearing MVs in patients with COVID-19 are suggested to be (i) early potential markers to predict the severity of COVID-19 (ii) a novel circulatory biomarker to evaluate the procoagulant activity and severity of COVID-19.
Sections du résumé
Background
UNASSIGNED
The hypercoagulability and thrombotic tendency in coronavirus disease 2019 (COVID-19) is multifactorial, driven mainly by inflammation, and endothelial dysfunction. Elevated levels of procoagulant microvesicles (MVs) and tissue factor-bearing microvesicles (TF-bearing MVs) have been observed in many diseases with thrombotic tendency. The current study aimed to measure the levels of procoagulant MVs and TF-bearing MVs in patients with COVID-19 and healthy controls and to correlate their levels with platelet counts, D-Dimer levels, and other proposed calculated inflammatory markers.
Materials and Methods
UNASSIGNED
Forty ICU-admitted patients with COVID-19 and 37 healthy controls were recruited in the study. Levels of procoagulant MVs and TF-bearing MVs in the plasma of the study population were measured using enzyme linked immunosorbent assay.
Results
UNASSIGNED
COVID-19 patients had significantly elevated levels of procoagulant MVs and TF-bearing MVs as compared with healthy controls (P<0.001). Procoagulant MVs significantly correlated with TF-bearing MVs, D-dimer levels, and platelet count, but not with calculated inflammatory markers (neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and platelet/neutrophil ratio).
Conclusion
UNASSIGNED
Elevated levels of procoagulant MVs and TF-bearing MVs in patients with COVID-19 are suggested to be (i) early potential markers to predict the severity of COVID-19 (ii) a novel circulatory biomarker to evaluate the procoagulant activity and severity of COVID-19.
Identifiants
pubmed: 35517897
doi: 10.2147/IDR.S355395
pii: 355395
pmc: PMC9064482
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2359-2368Informations de copyright
© 2022 Hamali et al.
Déclaration de conflit d'intérêts
The authors have read the journal’s policy and declare no conflict of interest.
Références
J Extracell Vesicles. 2021 Jul;10(9):e12117
pubmed: 34262673
Thromb Haemost. 2001 May;85(5):810-20
pubmed: 11372673
Am J Clin Pathol. 2021 Feb 11;155(3):364-375
pubmed: 33269374
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2311-5
pubmed: 10051638
Crit Care. 2020 Nov 16;24(1):647
pubmed: 33198786
Cell Mol Life Sci. 2005 May;62(9):971-88
pubmed: 15761668
Saudi Med J. 2021 Apr;42(4):370-376
pubmed: 33795491
Mol Neurobiol. 2021 Aug;58(8):4188-4215
pubmed: 34176095
Eur Respir Rev. 2016 Sep;25(141):266-77
pubmed: 27581826
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):878-882
pubmed: 33267656
J Med Virol. 2020 Apr;92(4):455-459
pubmed: 31994738
Circ Res. 2005 Jun 24;96(12):1233-9
pubmed: 15920023
Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1512-8
pubmed: 15890969
BMC Infect Dis. 2021 Jan 18;21(1):80
pubmed: 33461497
J Clin Invest. 1997 May 1;99(9):2118-27
pubmed: 9151784
Immunol Invest. 2021 Jan;50(1):92-100
pubmed: 32482134
Blood. 2000 Feb 1;95(3):930-5
pubmed: 10648405
J Extracell Vesicles. 2016 May 17;5:30829
pubmed: 27193612
Thromb Res. 2011 Feb;127 Suppl 3:S67-71
pubmed: 21262446
Atherosclerosis. 2001 Oct;158(2):277-87
pubmed: 11583705
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
EBioMedicine. 2021 May;67:103369
pubmed: 33971404
Thromb Res. 1993 Nov 15;72(4):295-304
pubmed: 8303669
PLoS One. 2013 Aug 02;8(8):e72663
pubmed: 23936542
Am J Obstet Gynecol. 2002 Aug;187(2):450-6
pubmed: 12193942
Thromb Haemost. 2001 Apr;85(4):639-46
pubmed: 11341498
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Blood Adv. 2021 Feb 9;5(3):628-634
pubmed: 33560376
J Immunol. 1998 Oct 15;161(8):4382-7
pubmed: 9780216
Exp Physiol. 2018 May 1;103(5):693-700
pubmed: 29469165
Clin Appl Thromb Hemost. 2004 Apr;10(2):133-41
pubmed: 15094933
Circulation. 2017 Jan 17;135(3):280-296
pubmed: 27821539
J Thromb Haemost. 2021 Sep;19(9):2268-2274
pubmed: 34236752
Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1687-93
pubmed: 17556654
Shock. 2020 Nov;54(5):652-658
pubmed: 32554992
Res Pract Thromb Haemost. 2021 May 18;5(4):e12525
pubmed: 34027292
Am J Respir Crit Care Med. 2011 Jul 15;184(2):224-32
pubmed: 21471087
PLoS One. 2021 Feb 22;16(2):e0246806
pubmed: 33617530
Lancet. 2020 Mar 21;395(10228):e52
pubmed: 32171074
J Transl Med. 2020 May 20;18(1):206
pubmed: 32434518
Eur Respir J. 2019 Oct 17;54(4):
pubmed: 31320458
Thromb Res. 2021 Oct;206:137-138
pubmed: 34479129
Am J Respir Crit Care Med. 2008 Mar 1;177(5):536-43
pubmed: 18006886
Thromb Haemost. 2005 Oct;94(4):853-8
pubmed: 16270642
Infect Drug Resist. 2021 Nov 23;14:4859-4864
pubmed: 34848978
PLoS One. 2015 Jan 14;10(1):e0116812
pubmed: 25587983
Am J Emerg Med. 2020 Mar;38(3):641-647
pubmed: 31785981
Semin Thromb Hemost. 2015 Oct;41(7):700-7
pubmed: 26408917
J Clin Med. 2021 Mar 04;10(5):
pubmed: 33806540
Kidney Int. 2006 Apr;69(8):1416-23
pubmed: 16531979
Blood. 2011 Mar 17;117(11):3172-80
pubmed: 21248061
J Thromb Haemost. 2008 Jun;6(6):913-9
pubmed: 18363818
Blood Adv. 2021 Feb 9;5(3):756-759
pubmed: 33560386
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994
ERJ Open Res. 2021 Jun 21;7(2):
pubmed: 34159187
Thromb Haemost. 2007 Nov;98(5):1096-107
pubmed: 18000616
J Med Virol. 2021 Apr;93(4):2221-2226
pubmed: 33135801
Blood Coagul Fibrinolysis. 1999 Jun;10(4):201-10
pubmed: 10390120
Thromb Haemost. 2007 Mar;97(3):425-34
pubmed: 17334510
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143